AusCann inks deal with MediPharm Labs

Company News

by Anna Napoli

Medical cannabis company AusCann Group (ASX:AC8) has provided a quarterly update to the market flagging a deal with MediPharm Labs.

AusCann has inked a deal to purchase cannabis resin from MediPharm Labs, Canada’s largest supplier of purified, pharmaceutical grade cannabis extracts.

The resin will be used in the development and production of AusCann’s first line of hard shell capsules, and AusCann says it is on track to release its hard shell capsules to the market for clinical trials during 2019.

AusCann has also announced the appointment of Ido Kanyon as its new CEO, he will take the reigns on May 22nd.

Shares in AusCann (ASX:AC8) are trading 1.37 per cent higher at $0.37.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.